Empower Pharmacy, a Houston-based compounding pharmacy operating as both a 503A traditional compounding pharmacy and a 503B outsourcing facility, faces ongoing federal litigation from Eli Lilly and Company. The suit centers on allegations that Empower unlawfully compounded and marketed large quantities of tirzepatide-containing products, the active ingredient in Lilly’s FDA-approved medications Mounjaro and Zepbound.
This case highlights broader tensions in the compounding pharmacy sector following the resolution of national shortages for certain GLP-1 receptor agonist drugs. As of April 2026, the litigation remains in the motion-to-dismiss phase in federal court, with no trial date scheduled. Parallel regulatory scrutiny from the U.S. Food and Drug Administration (FDA) and state boards, including California’s efforts to revoke probation on Empower’s nonresident sterile compounding permit, adds layers of complexity.
The developments matter to patients seeking affordable alternatives to brand-name weight-management and diabetes treatments, prescribers relying on compounded formulations, and the compounding industry navigating post-shortage restrictions under federal law. This article provides a factual overview of the lawsuit, regulatory context, and current status based on court records and agency actions.
Background & Legal Context
Compounding pharmacies prepare customized medications for individual patients when commercially available drugs do not meet specific needs, such as dosage adjustments or allergen avoidance. Congress enacted the Drug Quality and Security Act (DQSA) in 2013 to strengthen oversight after a deadly fungal meningitis outbreak linked to contaminated compounded steroids. The law created Section 503A for traditional compounding pharmacies and Section 503B for outsourcing facilities that produce sterile drugs in larger quantities under current good manufacturing practices (cGMP).
Outsourcing facilities registered under Section 503B receive exemptions from certain FDCA requirements, including premarket approval, but must adhere to strict sterility, labeling, and quality standards enforced by the FDA. When the FDA determines that a drug shortage has ended, compounding of that drug generally becomes restricted unless it meets narrow exceptions, such as a documented clinical difference for an individual patient under Section 503A.
Tirzepatide, the active pharmaceutical ingredient in Lilly’s Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management), experienced significant shortages starting in 2022. The FDA resolved the tirzepatide shortage in late 2024 and early 2025, triggering enforcement actions against compounders continuing large-scale production.
Empower Pharmacy has operated facilities in Houston, Texas, producing both patient-specific compounded drugs and larger batches through its 503B registration. The company has faced prior FDA inspections and state disciplinary actions dating back more than a decade, including warning letters in 2017 and 2021 related to cGMP deviations.
Key Legal Issues Explained
The core dispute in the Empower Pharmacy lawsuit involves the boundary between permissible compounding and what Lilly characterizes as unauthorized commercial manufacturing and false advertising. Under the Lanham Act (15 U.S.C. § 1125), companies may sue competitors for false or misleading statements in commercial advertising that cause commercial injury. Lilly alleges Empower’s marketing materials referenced Lilly’s clinical trial data in ways that implied the compounded products were equivalent in safety and efficacy to the approved drugs, even after shortages ended.
Lilly further claims violations of state consumer protection statutes by allegedly selling “knockoff” versions without FDA approval or adequate testing. Empower maintains that its activities fall within lawful compounding practices for patients with legitimate medical needs and has described the suit as an anticompetitive effort by a brand-name manufacturer to limit access to lower-cost alternatives.
A separate but related set of issues arises under the FDCA. The FDA’s April 2025 warning letters (WL #700964 and WL #700962) to Empower’s two Houston facilities cited repeated deficiencies in sterile drug production, including inadequate environmental monitoring, failure to perform media fills under worst-case conditions, equipment sterilization lapses, and labeling omissions that disqualified 503B exemptions. Such violations can render drugs “adulterated” or “misbranded,” exposing the pharmacy to potential enforcement actions such as injunctions or seizures.
These regulatory findings intersect with the private lawsuit because courts often consider FDA observations when assessing patient-safety claims in Lanham Act cases.
Latest Developments or Case Status
Eli Lilly filed its initial complaint against Empower on April 1, 2025, in the U.S. District Court for the District of New Jersey (Case No. 2:25-cv-02183). The company voluntarily dismissed that action and refiled on July 25, 2025, in the U.S. District Court for the Southern District of Texas (Case No. 4:25-cv-03464), where Empower is headquartered.
Empower responded with a motion to dismiss filed in October 2025, contending that Lilly’s claims fall outside the scope of private enforcement under federal drug laws and instead represent anticompetitive conduct. As of April 2026, the motion remains pending before the court. Recent docket activity includes a motion for a protective order filed by Empower in March 2026. No hearing or ruling on the motion to dismiss has been issued, and no trial date has been set.
On the regulatory front, the FDA issued two formal warning letters on April 2, 2025, following inspections conducted in August-October 2024. The agency continues to monitor compliance. In California, the State Board of Pharmacy moved in late 2025 to revoke Empower’s probation (imposed in 2022 after allegations involving inferior ingredients in vitamin injections). The board cited new reports of patients becoming ill after receiving compounded drugs, including GLP-1 products, from 2022-2023. Proceedings to revoke the probation remain active as of February 2026, potentially resulting in a ban on shipping to California patients.
Who Is Affected & Potential Impact
Patients prescribed compounded tirzepatide or similar GLP-1 medications for diabetes or weight management represent the largest group potentially affected. Many rely on compounded versions for affordability or specific formulations unavailable in brand-name products. Any disruption in supply or increased regulatory restrictions could raise costs or limit access.
Prescribing physicians and telehealth providers must now more carefully document clinical justifications when ordering compounded versions to comply with post-shortage rules. Healthcare institutions and pharmacies that source from 503B facilities face heightened compliance obligations.
The broader compounding pharmacy industry watches the case closely. A ruling favoring Lilly could encourage additional private lawsuits against other compounders and reinforce FDA restrictions. Conversely, dismissal on jurisdictional or preemption grounds could clarify limits on brand-name manufacturers’ ability to use the Lanham Act against competitors in regulated drug markets.
What This Means Going Forward
This litigation and concurrent FDA and state actions underscore the evolving enforcement landscape for compounding pharmacies after the DQSA and post-pandemic drug shortages. Courts will likely continue examining the interplay between federal preemption of drug safety regulation and private rights of action for false advertising.
Stakeholders should monitor the Texas federal court’s ruling on the motion to dismiss, any FDA follow-up enforcement, and the outcome of California’s probation revocation proceedings. Industry groups and patient advocacy organizations have emphasized the need for balanced oversight that protects safety without unduly restricting patient access to medically necessary compounded drugs.
Frequently Asked Questions
What is the Empower Pharmacy lawsuit primarily about?
The lawsuit filed by Eli Lilly alleges that Empower Pharmacy engaged in large-scale compounding and misleading marketing of tirzepatide products after the FDA resolved related shortages, in violation of the Lanham Act and state consumer protection laws.
What stage is the Eli Lilly v. Empower case in as of April 2026?
The case (No. 4:25-cv-03464, S.D. Tex.) is in the pretrial phase. Empower’s motion to dismiss, filed in October 2025, remains pending with no trial date set.
How do the FDA warning letters affect Empower Pharmacy?
The April 2025 warning letters (WL #700964 and #700962) detail sterility and quality-control failures at Empower’s Houston facilities. They do not constitute final enforcement but signal potential future agency action if deficiencies are not corrected.
Can patients still obtain compounded tirzepatide from Empower Pharmacy?
Availability depends on individual state licensing rules, prescriber documentation of clinical need, and Empower’s ongoing compliance with federal and state requirements. Patients should consult their healthcare providers for current options.
What is the status of California’s action against Empower Pharmacy?
California’s Board of Pharmacy is seeking to revoke probation placed on Empower’s nonresident sterile compounding permit in 2022. The revocation petition, filed in late 2025, cites new patient-safety concerns and remains under review.
Does the lawsuit affect other compounding pharmacies?
While the case targets Empower specifically, similar suits by Lilly against other compounders and broader FDA policy changes have industry-wide implications for GLP-1 compounding practices.
Conclusion
The Empower Pharmacy lawsuit and accompanying regulatory developments reflect ongoing efforts to balance innovation in personalized medicine with rigorous safety standards under the Federal Food, Drug, and Cosmetic Act. As the Texas federal court considers dispositive motions and state boards complete their reviews, the outcome will help define permissible boundaries for compounding pharmacies in a post-shortage environment.
This article is for informational purposes only and does not constitute legal advice. Readers should consult qualified counsel for advice specific to their circumstances and monitor official court dockets and FDA announcements for the most current information.
You may also like: Capital One Outage Class Action Lawsuit: Eligibility & Claims (2026)